Children living with a rare muscle wasting condition could soon benefit from wider access to a specialist treatment after NHS officials approved the drug for use across England.
The decision has been described by campaigners and medical charities as a major step forward for families affected by spinal muscular atrophy, often known as SMA.
SMA is a rare inherited condition that causes progressive muscle weakness and movement difficulties. In severe cases, it can affect breathing, mobility and basic physical development during childhood.
The treatment approval follows a long period of campaigning by families, clinicians and patient groups who argued that earlier access to specialist medication could significantly improve quality of life for affected children.
Health officials said the decision was based on clinical evidence showing the treatment could help slow progression of the disease and improve physical outcomes for some patients.
Medical experts have described the development as particularly important because rare diseases often struggle to receive rapid funding approval due to the high cost of specialist medicines.
Families affected by SMA said the announcement offers hope after years of uncertainty. Several parents involved in campaigning efforts said access to treatment could change long term outcomes for younger patients diagnosed early.
The NHS said treatment access would follow specialist clinical assessment, with hospitals and neuromuscular care teams expected to begin preparing for wider rollout arrangements.
Charities supporting families affected by muscle wasting conditions welcomed the announcement and said continued investment into rare disease research remained essential.